158 related articles for article (PubMed ID: 9836553)
21. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.
Ornstein DK; Smith DS; Andriole GL
Urology; 1998 Dec; 52(6):1094-7. PubMed ID: 9836561
[TBL] [Abstract][Full Text] [Related]
22. Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer. Canadian Prostate Health Council.
Ramsey EW; Elhilali M; Goldenberg SL; Nickel CJ; Norman R; Perreault JP; Piercy B; Trachtenberg J
J Urol; 2000 Feb; 163(2):499-502. PubMed ID: 10647665
[TBL] [Abstract][Full Text] [Related]
23. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
24. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
Naito S
Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
[TBL] [Abstract][Full Text] [Related]
25. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound.
Abi-Aad AS; Macfarlane MT; Stein A; deKernion JB
J Urol; 1992 Mar; 147(3 Pt 2):952-5. PubMed ID: 1371567
[TBL] [Abstract][Full Text] [Related]
26. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins.
Connolly JA; Shinohara K; Presti JC; Carroll PR
Urology; 1996 Feb; 47(2):225-31. PubMed ID: 8607239
[TBL] [Abstract][Full Text] [Related]
27. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
28. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging.
Linder BJ; Kawashima A; Woodrum DA; Tollefson MK; Karnes J; Davis BJ; Rangel LJ; King BF; Mynderse LA
Can J Urol; 2014 Jun; 21(3):7283-9. PubMed ID: 24978358
[TBL] [Abstract][Full Text] [Related]
29. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy.
Foster LS; Jajodia P; Fournier G; Shinohara K; Carroll P; Narayan P
J Urol; 1993 May; 149(5):1024-8. PubMed ID: 7683341
[TBL] [Abstract][Full Text] [Related]
30. Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.
Ariane MM; Ploussard G; Rebillard X; Malavaud B; Rischmann P; Hennequin C; Mongiat-Artus P
World J Urol; 2015 Nov; 33(11):1741-7. PubMed ID: 25822706
[TBL] [Abstract][Full Text] [Related]
31. Current trends in prostate cancer diagnosis and staging among United States urologists.
Plawker MW; Fleisher JM; Vapnek EM; Macchia RJ
J Urol; 1997 Nov; 158(5):1853-8. PubMed ID: 9334616
[TBL] [Abstract][Full Text] [Related]
32. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
33. Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?
Rubin MA; Bismar TA; Curtis S; Montie JE
Am J Surg Pathol; 2004 Jul; 28(7):946-52. PubMed ID: 15223967
[TBL] [Abstract][Full Text] [Related]
34. Disease recurrence after radical prostatectomy. Contemporary diagnostic and therapeutical strategies.
Augustin H; Hammerer PG
Minerva Urol Nefrol; 2003 Dec; 55(4):251-61. PubMed ID: 14765017
[TBL] [Abstract][Full Text] [Related]
35. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
36. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy.
Leventis AK; Shariat SF; Kattan MW; Butler EB; Wheeler TM; Slawin KM
J Clin Oncol; 2001 Feb; 19(4):1030-9. PubMed ID: 11181666
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy.
Naya Y; Okihara K; Evans RB; Babaian RJ
Urology; 2005 Aug; 66(2):350-5. PubMed ID: 16040095
[TBL] [Abstract][Full Text] [Related]
38. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
39. British urological surgery practice: 1. Prostate cancer.
Savage P; Bates C; Abel P; Waxman J
Br J Urol; 1997 May; 79(5):749-54; discussion 754-5. PubMed ID: 9158514
[TBL] [Abstract][Full Text] [Related]
40. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
